Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.
about
Primary Aldosteronism: Changing Definitions and New Concepts of Physiology and Pathophysiology Both Inside and Outside the Kidney.Curable hypertension.Graz Endocrine Causes of Hypertension (GECOH) study: a diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronism.Laboratory investigation of primary aldosteronism.Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism.Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension.Randomized Polypill crossover trial in people aged 50 and over.Plasma renin activity and its association with ischemic heart disease, congestive heart failure, and cerebrovascular disease in a large hypertensive cohort.Current views on the diagnosis and management of hypokalaemia in children.Guidelines for the management of the incidentally discovered adrenal mass.Aldosterone-to-renin ratio acts as the predictor distinguishing the primary aldosteronism from chronic kidney disease.Primary aldosteronism--actual epidemics or false alarm?The pharmacological treatment of primary aldosteronism.Optimal use and interpretation of the aldosterone renin ratio to detect aldosterone excess in hypertension.Primary aldosteronism: diagnosis and treatment.Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension.Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronismPrimary aldosteronism: renaissance of a syndrome.Diagnosis and treatment of low-renin hypertension.Plasma renin activity and aldosterone concentrations in hypertensive cats with and without azotemia and in response to treatment with amlodipine besylate.Influence of doxazosin on biosynthesis of S100A6 and atrial natriuretic factor peptides in the heart of spontaneously hypertensive ratsEndocrine and hypertensive disorders of potassium regulation: primary aldosteronismAldosterone as an independent factor in cerebrovascular damage.Plasma renin activity and risk of cardiovascular and mortality outcomes among individuals with elevated and nonelevated blood pressureProgress in primary aldosteronism: present challenges and perspectivesPrimary aldosteronism: A Japanese perspective.A comprehensive review of the clinical aspects of primary aldosteronism.Resistant hypertension and undiagnosed primary hyperaldosteronism detected by use of a computerized database.Primary aldosteronism: from bench to bedside.Coaxial guide wire placement in the right adrenal vein for repeated adrenal venous samplings.Pathophysiology, diagnosis, and treatment of mineralocorticoid disorders.Issues in the Diagnosis and Treatment of Primary Aldosteronism.Management of Adrenal Masses.Diagnosing endocrine hypertension: a practical approach.Screening for primary aldosteronism in a primary care unit.Screening for primary aldosteronism in an argentinian population: a multicenter prospective study.Long-term use of aldosterone-receptor antagonists in uncontrolled hypertension: a retrospective analysis.Familial mineralocorticoid induced hypertension in the sultanate of oman.Predictors of malignancy in primary aldosteronism.Periodic drop thumb, hypokalemia and adrenal adenoma.
P2860
Q30248429-ABE5D53E-32D1-4638-ADB3-8EA86669CE95Q33383982-77C94ADE-F5E7-4572-881A-6B7FF406B349Q33427667-001735C2-F1F7-4F77-8542-C63CC2105D80Q33868500-43588E78-F5D3-47B7-97B4-96F299FA4691Q33930728-6242EE17-DBDD-47DE-AB6D-6837D3D5A48DQ34058175-5A34955D-9277-43FB-AD2D-2BC851DF270CQ34345933-B6C0EB5E-FF84-4BF0-8AAF-BC8FF3EE6E50Q34475438-D7F10AA3-38AF-4FB9-A1A0-9B76D7444A04Q34518002-38587A8D-CE34-4480-A568-6E4764B33ED8Q35137847-224C12CA-BCDF-42B9-A7C9-E49E83F13744Q35919186-7978A0C7-4EE8-4920-990E-19DD96CE484BQ36068319-83303510-45FB-4062-B829-3FD3CF77EC9CQ36428495-AF212AAD-8E4C-48F6-86D1-90194AE0EDFBQ36450459-DE1F8E0D-04FC-41D3-A595-E88D9E8F07ACQ36684808-70B72D7F-D68D-4B24-ABB1-B90B13C85E70Q36686822-CF39140F-C577-4E55-B6B5-44095B225A6AQ36740791-F5A2D4F0-E135-4A80-87F8-6F12D51F5399Q36817162-3A84623E-433F-47BE-AA09-2F5261817251Q36851195-6481D440-C9CF-4C59-B03F-ADDB1AB9BA82Q36975232-084E1EA9-0DA8-4622-838F-2C15D4DDEB74Q37071624-DF2CE0FF-C612-4D99-93AE-A29D87651D82Q37107686-2E2AC214-D648-4EC5-B314-6403A91BDB53Q37330163-3D374397-04CF-40E0-819A-45C3076DDEC5Q37480881-085C3A20-27E9-4BFB-8E78-77A56E1E8B48Q37679032-A81C1570-91FD-4848-8DFD-287EAC0F6DA6Q37838327-FFBF2D59-520F-4374-A9A2-DEAC6732118AQ37879448-C915BF44-D9B2-4317-AE66-B39E5B1169AEQ37901559-38481479-6B67-4274-BC24-CF7ABB9709B6Q37951385-373E9CC2-037D-46D2-91CF-35EB6FEC55C6Q38170250-E72D065F-4AFB-40C5-9F39-7A52F3B911A9Q38221451-D54A7D5E-6B66-477B-A2F9-9F34033A363DQ38411728-6679FC9B-549E-4083-9779-32C894E59B86Q39105776-75692D4F-71CA-4F24-9376-7D2938874C7EQ39337899-CE29E510-2DD5-4505-A150-19379B70DDF8Q39526801-53E5A092-A42F-4619-9031-9DCDE7D93A35Q41534932-643DF089-D802-4DDC-87D2-953450E9BFDAQ41814119-09E9B489-47EA-4856-B174-B27051E8D253Q41976354-F2B9C755-F006-4D8F-B3B6-CE74EEF04AAFQ42618947-1EE844B3-6921-4B8D-8E8F-EB64CC367A87Q42759599-E442A573-FB86-4B19-B94B-0F1309DF3EE8
P2860
Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.
@en
Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.
@nl
type
label
Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.
@en
Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.
@nl
prefLabel
Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.
@en
Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.
@nl
P2093
P50
P1433
P1476
Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism
@en
P2093
Cristina Paglieri
Franco Veglio
Livio Chiandussi
Paolo Mulatero
P304
P356
10.1161/01.HYP.0000038478.59760.41
P407
P577
2002-12-01T00:00:00Z